Maria Carell new CEO for Q-Med AB

Press conference April 27, 10.30 a.m. - 11.30 a.m.

Maria Carell will succeed Bengt Ågerup as CEO of Q-Med AB on September 1, 2010.
Maria comes from Actavis, where she has successfully built up the Swedish
business since 2005.

"I am delighted and proud to be able to present Maria Carell as the new CEO of
Q-Med after Bengt Ågerup. Maria Carell brings with her broad experience from the
health and pharmaceutical sector, and furthermore she is a successful and
innovative leader who can build relations and further develop Q-Med's market
proficiency in an increasingly competitive world. She will contribute with
competence, commitment and not least of all very clear leadership," says Anders
Milton, Chair of Q-Med AB.

"I have come to know Maria as someone with drive and good judgement," continues
Bengt Ågerup, founder and CEO of Q-Med. "She has shown a great ability to create
growth and lead a complex business. Q-Med holds a special position in the
industry, with several leading and respected brands. It will be very inspiring
to see Maria Carell as my successor."

Bengt Ågerup will continue as CEO until Maria Carell takes up her appointment.

Maria Carell was born in 1973, and is an economist with an international
profile. She has a long and solid background of leading positions in the
pharmaceutical industry. She now comes from Actavis, one of the world's leading
companies within the development, manufacture and sales of generic
pharmaceuticals, where she has been the Country Manager for Sweden. Maria Carell
also has experience of entrepreneurial companies, where she has worked within
marketing and sales of consumer products.

More information will be given at the press conference today
Tuesday, April 27 at the Nordic Light Hotel in Stockholm, Vasaplan 7
10.30 a.m. - 11.30 a.m.


Queries should be addressed to:
Karin Falck, PR & Corporate Communications
Tel: +46 70 974 9015


Q-Med AB is a medical device company that develops, manufactures, markets, and
sells high quality medical implants for esthetic and medical use. The majority
of the products are based on the company's patented technology, NASHA(TM), for
the production of stabilized non-animal hyaluronic acid. The product portfolio
today contains: Restylane® for filling lines and folds, contouring and creating
volume in the face, Macrolane(TM) for body contouring, Durolane(TM) for the
treatment of osteoarthritis of the hip and knee joints, Deflux® for the
treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder)
in children, and Solesta® for the treatment of fecal incontinence. Sales are
made through the company's own subsidiaries or distributors in over 70
countries. Q‑Med today has about 650 coworkers, with almost 400 at the company's
head office and production facility in Uppsala, Sweden. Q-Med AB is listed in
the Mid Cap segment of the NASDAQ OMX Nordic.


Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail:info@q-med.com
<mailto:info@q-med.com>. Web: www.q-med.com <http://www.q-med.com/>.


[HUG#1408484]